Logo

Prodesse Licenses LUX from Invitrogen

Jul 21, 2006

NEW YORK, July 21 (GenomeWeb News) - Prodesse licensed the LUX technology from Invitrogen to develop its first diagnostic assays, Invitrogen said today.

 

The technology would allow Prodesse to provide customers with state-of-the-art molecular diagnostic products, Invitrogen said. Invitrogen gains a new customer base and enters new market segments, under the agreement.

 

According to the company, LUX, combined with SuperScript III Reverse Transcriptase and Platinum Tfi DNA Polymerase LUX offers a complete platform for assay development.

 

 

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.